LKFT — Lakefront Biotherapeutics N.V. stock price, charts and financials

QT44Lakefront Biotherapeutics N.V.

Lakefront Biotherapeutics N.V. (NASDAQ: LKFT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
26.45
-0.29-1.08%
OverviewShort InterestFilings
LKFTQT44Lakefront Biotherapeutics N.V.·NASDAQ
26.45-1.08%
TA
Loading chart...
Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E3.05EPS (ttm)8.68Insider Own-Shs Outstand65.90MPerf Week-6.04%
Market Cap1.74BForward P/E-EPS next Y-3.05Insider Trans-Shs Float49.19MPerf Month-12.85%
Enterprise Value1.72BPEG-EPS next Q-Inst Own-Short Float4.72%Perf Quarter-7.06%
Income572.00MP/S1.44EPS this Y-146.54%Inst Trans-Short Ratio14.25Perf Half Y-22.73%
Sales1.21BP/B0.46EPS next Y24.49%ROA14.49%Short Interest2.32MPerf YTD-19.11%
Book/sh57.07P/C0.51EPS next 5Y-ROE16.88%52W High37.78 -29.99%Perf Year-19.14%
Cash/sh52.31P/FCF-EPS past 3/5Y-ROIC18.22%52W Low26.39 0.23%Perf 3Y-36.75%
Dividend Est.-EV/EBITDA3.14Sales past 3/5Y-Gross Margin98.01%Volatility2.14% 1.95%Perf 5Y-56.19%
Dividend TTM-EV/Sales1.43EPS Y/Y TTM-Oper. Margin57.14%ATR (14)0.63Perf 10Y-50.10%
Dividend Ex-Date-Quick Ratio30.30Sales Y/Y TTM-Profit Margin46.83%RSI (14)27.10Recom3.00
Dividend Gr. 3/5Y-Current Ratio30.48EPS Q/Q109.25%SMA20-8.01%Beta0.27Target Price30.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-7.84%Rel Volume1.90Prev Close26.74
Employees452LT Debt/Eq0.00EarningsAug 10SMA200-14.11%Avg Volume174.67KPrice26.45
IPO DateMay 05, 2005Option/ShortYes / YesEPS/Sales Surpr.122.39% -32.03%Net Debt/EBITDA-0.13Volume331,483Change-1.08%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-10-26ResumedMorgan StanleyEqual Weight$30
Latest News
Jul-28-26
Jul-28-2604:01PM
Inkoop van eigen aandelenglobenewswire.com
04:01PM
Acquisition of Own Sharesglobenewswire.com
Jul-21-26
Jul-21-2604:01PM
Acquisition of Own Sharesglobenewswire.com
Jul-14-26
Jul-14-2604:01PM
Acquisition of Own Sharesglobenewswire.com
Jul-13-26
Jul-13-2604:01PM
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofiglobenewswire.com
04:01PM
Lakefront kondigt het terugtreden van Paulo Fontoura uit de Raad van Bestuur aan na zijn benoeming tot Global Head of Research & Development bij Sanofiglobenewswire.com
Jul-07-26
Jul-07-2604:01PM
Acquisition of Own Sharesglobenewswire.com
Jun-30-26
Jun-30-2604:01PM
Acquisition of Own Sharesglobenewswire.com
Jun-29-26
Jun-29-2604:03PM
Lakefront Biotherapeutics Receives Transparency Notification As Madison Avenue Partners Crossed Above 5% Of Voting RightsBenzinga
04:01PM
Lakefront Receives Transparency Notification from Madison Avenue Partnersglobenewswire.com
Jun-16-26
Jun-16-2604:03PM
Lakefront Biotherapeutics Repurchases 38,537 Of Its Own Shares Through June 9 - June 12Benzinga
Company

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
Total Revenue1,2141,255
Cost of Goods Sold Incl. D&A2534
Gross Profit1,1901,221
Selling, General and Administrative Excl. Other120126
Research and Development355518
Other Operating Expense1912
Operating Income695566
Interest Expense03
Unusual Expense
——
Non-Operating Income (Expense)-145-224
Net Income Before Taxes551339
Income Taxes-19-21
Consolidated Net Income572362
Net Income From Continuing Operations571360
Net Income572362
EPS (Recurring)8.685.49
EPS (Basic, Before Extraordinaries)8.685.49
EPS (Diluted)8.685.49
EBITDA557405
Other After Tax Adjustments
——
Stock Option Compensation Expense
——
Price To Earnings Ratio3.055.95
Price To Sales Ratio1.441.72
Gross Margin98.0297.29
Operating Margin57.2545.10
Net Margin47.1228.84
Shares Outstanding6666
Market Capitalization1,7462,158
Operating Lease Expense
——
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.